Chemical Component Summary

FormulaC18 H20 O2
Molecular Weight268.35
Isomeric SMILESCC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1

Chemical Details

Formal Charge0
Atom Count40
Chiral Atom Count0
Chiral Atomsn/a
Bond Count41
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00255 Different stereochemistry
DescriptionA synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
  • (E)-3,4-bis(4-hydroxyphenyl)-3-hexene
  • (e)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
  • 4,4'-Dihydroxy-alpha,beta-diethylstilbene
  • 4,4'-dihydroxy-α,β-diethylstilbene
  • alpha,Alpha'-diethyl-(e)-4,4'-stilbenediol
  • Diethylstilbestrol diphosphate
  • Diethylstilbestrol diphosphate sodium
Brand Names
  • Honvol Ampoules 250mg
  • Honvol Tablets 100mg
  • Stilbestrol 0.5mg Tablet
  • Stilbestrol 1.0mg Tablet
  • Stilbes
Affected OrganismHumans and other mammals
IndicationUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
PharmacologyDiethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
Mechanism of actionEstrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Route of administration
  • Intravenous
  • Oral
  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • BCRP/ABCG2 Inhibitors
  • Benzene Derivatives
  • Benzylidene Compounds
  • L02AA01
  • G03CC05
  • L02AA04
  • G03CB02
CAS number56-53-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682